Liquidia Corporation Form 8-K Summary
Business Context and Reporting Period
Liquidia Corporation filed a Form 8-K reporting management changes and related executive compensation arrangements. The earliest reported event date was June 15, 2022; the report was signed on June 22, 2022. The filing does not report quarterly or annual financial results.
Key Financial and Operating Information
- No revenue, profit, cash flow, margin, debt, liquidity, or balance-sheet metrics are provided.
- Incoming Chief Medical Officer Rajeev Saggar will receive an annual base salary of $475,000 and is eligible for a discretionary annual cash bonus of up to 40% of base salary.
- Dr. Saggar will receive a $50,000 sign-on bonus, subject to repayment under specified termination conditions.
- He will receive a nonqualified option to purchase up to 200,000 shares, with an exercise price equal to the fair market value on the grant date.
- He will also receive restricted stock units valued at $350,000 based on the fair market value of the Company’s common stock on the grant date.
Material Changes Versus the Prior Comparable Period
- Former Chief Medical Officer Tushar Shah’s employment terminated effective June 15, 2022. The Company and Dr. Shah were working to finalize a severance agreement and general release; final terms are not provided.
- Dr. Saggar was appointed Chief Medical Officer on June 7, 2022, effective July 18, 2022, succeeding Dr. Shah.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Dr. Saggar’s employment is at will. His base salary may be reduced by up to 10% if the Board determines a reduction is necessary due to the Company’s financial condition and applies an equal percentage reduction to all executive officers’ base salaries.
- If terminated without Cause or if he resigns for Good Reason, Dr. Saggar may receive nine months of salary continuation, qualifying bonus amounts, and certain COBRA health-coverage payments, subject to release and other conditions.
- Following a qualifying Change in Control, the severance period increases to 12 months, the bonus is payable at the target amount, and certain unvested equity may fully vest if assumed or continued by the surviving entity.
- The option vests 25% after one year, with the remainder vesting monthly over the following 36 months. The RSUs vest 50% after one year and the remainder quarterly over two years, subject to continued employment, with specified accelerated vesting provisions.
- The filing does not provide a financial outlook, product guidance, or updated liquidity assessment.
Investor Verification Priorities
- Verify the final severance terms, if any, agreed with former Chief Medical Officer Tushar Shah.
- Review Exhibit 10.1 for the complete employment, severance, equity, and Change in Control provisions applicable to Dr. Saggar.
- Assess the potential dilution and compensation expense associated with the 200,000-share option and $350,000 RSU award.
- Confirm Dr. Saggar’s July 18, 2022 start date and the actual fair market value used to determine the option exercise price and RSU share count.
- Obtain the Company’s financial statements or subsequent filings for revenue, cash usage, liquidity, debt, and any other financial metrics not included in this 8-K.